title: [Bone marrow aplasia associated to the use of ticlopidine].
abstract: We report a 58 years old male that developed a bone marrow aplasia associated to the use of ticlopidine, prescribed after coronary artery stenting. The patient developed a pneumonia as a complication. He was admitted to the Intermediate Treatment Unit, receiving wide spectrum antimicrobial therapy and a granulocyte colony stimulating factor (Neupogen(r)) with favourable response. Ticlodipine is an effective antiplatelet agent, but has serious hematological and other side effects. Its prescription requires a close follow up and search for complications.
authors.affiliation: Facultad de Ciencias Médicas, Universidad de Santiago de Chile.
authors.forename: Carolina
authors.initials: C
authors.lastname: Ruiz
authors.forename: Tatiana
authors.initials: T
authors.lastname: Monroy
authors.forename: Nelson
authors.initials: N
authors.lastname: Montaña
authors.forename: Pilar
authors.initials: P
authors.lastname: Lora
authors.forename: Rubén
authors.initials: R
authors.lastname: Lamich
authors.forename: Alejandro
authors.initials: A
authors.lastname: Valderrama
mesh_terms: D001855:Bone Marrow Diseases / Q000139:chemically induced*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D011994:Recombinant Proteins; D013988:Ticlopidine / Q000009:adverse effects*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D013988:Ticlopidine; D000069585:Filgrastim